GO
Loading...

Amgen Inc

More

  • Many analysts are facing this week's flood of earnings with a healthy dose of skepticism, knowing that results will once again have to exceed Wall Street's expectations to continue the market's advance.   The earnings parade comes as the Dow Jones Industrial Average and the S&P 500 trade at record highs with the blue-chip index touching 14,000 for the first time.  But rally aside, analysts believe there are still issues hanging over the market, which have caused a large share of the volatility since June.

  • It's Time for the Lightning Round! Thursday, 12 Jul 2007 | 10:33 AM ET

    Moody's, AT&T, Whirlpool and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Court Rules in Favor of Ariad in Eli Lilly Suit Monday, 9 Jul 2007 | 5:26 PM ET

    Ariad Pharmaceuticals said a U.S. federal court ruled in favor of it and co-complainants in a patent infringement case against Eli Lilly, saying that the patent was valid and enforceable.

  • Amgen said on Monday it has agreed to buy privately held Ilypsa, which is developing a drug for chronic kidney disease, for $420 million in cash.

  • It's Time for the Lightning Round! Monday, 21 May 2007 | 10:13 AM ET

    Amgen, Budweiser, Disney and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Which Retail Pick Brings The Guys To Blows? Thursday, 17 May 2007 | 8:33 PM ET

    In this feature CNBC Contributor Herb Greenberg takes down the traders over their picks. Click here to find out which hot stock has Herb and Jeff Macke in opposite corners.

  • Amgen Shares Drop On More Anemia-Drug Fallout Tuesday, 15 May 2007 | 12:00 PM ET

    Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.

  • No. 2 - Bio-Hazard Monday, 14 May 2007 | 1:08 PM ET

    Sometimes the stocks that trade on hope lead only to despair. Investors in biotech companies Amgen (AMGN) and Dendreon (DNDN) suffered serious side effects this week as the FDA raised questions about the safety and effectiveness of their flagship drugs. Is there any hope for a sector that trades on hope?

  • Supreme Court Declines Review of Amgen Patent Dispute Monday, 14 May 2007 | 12:55 PM ET

    The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.

  • CNBC's Domm: Today's Agenda in the Markets Monday, 14 May 2007 | 8:51 AM ET

    Stocks are looking for direction amid a flurry of takeover headlines this morning. Asian stocks were higher overnight on the back of Wall Street's Friday gains, but European markets are mostly weaker.

  • Stocks ended broadly higher after new economic data raised hopes of a Fed rate cut, and investors were quick to jump back into the market following recent declines. "I'm not surprised to see the market snap back," said Alec Young, market strategist at S&P Equity Research. "The market was kind of overbought -- it was an excellent opportunity for a shakeout."

  • Amgen Shares Fall on Downgrades, Anemia-Drug Ruling Friday, 11 May 2007 | 2:12 PM ET

    Several investment banks slashed their ratings on Amgen shares following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and Johnson & Johnson.

  • M&A news and analyst actions were some of the catalysts behind the most actively traded stocks on Friday.

  • CNBC's Domm: Today's Agenda in the Markets Friday, 11 May 2007 | 8:50 AM ET

    Stocks will take their direction from economic data today after yesterday's drenching from negative April chain store sales took the Dow down 147 points and bit 1.7% off the Nasdaq and 1.4% off the S&P 500. European markets are lower, following overnight weakness in Asian markets.

  • The Word on the JetBlue Shakeup, The Milk Ripple... Thursday, 10 May 2007 | 8:37 PM ET

    The guys go behind the headlines and give you their take on ... JetBlue's CEO being forced out ... the latest company to miss earnings over milk prices ... and more.

  • Stocks sold off across the board, and the Dow fell almost 150 points, after mixed economic data prompted investors to book gains.  "A day like today was inevitable," said Michael Cuggino of Permanent Portfolio Funds. "I would caution investors not to get overly concerned based on today's (economic) statistics."

  • FDA Panel Recommends Stricter Labeling on Anemia Drugs Thursday, 10 May 2007 | 4:21 PM ET

    Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.

  • Dendreon TV Thursday, 10 May 2007 | 11:35 AM ET

    While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.

  • U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.

  • It's Time for the Lightning Round! Friday, 4 May 2007 | 6:55 PM ET

    Sears, Bank of New York, Amgen and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

Most Popular Video

Wednesday, 16 Apr 2014 | 10:41 AM ET

CNBC's Dominic Chu digs into the year-to-date S&P performance of the airlines and explains why it has been the lone bright spot for the industrial sector.

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.

Wednesday, 16 Apr 2014 | 12:35 PM ET

Intel CEO Brian Krzanich discusses some signs of stability in enterprise in the mature markets, and whether the emerging markets area steadying as well.